A case of renal cell carcinoma with multiple lung metastases refractory to interferon-α showing complete remission by interleukin-2 monotherapy

International Journal of Urology

Volumn 13, Issue 6, 2006, Pages 805-808

  Hayashi, Tetsuya ^a   Miyagawa, Yasushi ^a   Tsujimura, Akira ^a   Nonomura, Norio ^a   Minami, Masato ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Interferon ; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; IMUNACE 35; INTERLEUKIN 2; OIF;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FATIGUE; FEVER; HEMATURIA; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MONOTHERAPY; NEPHRECTOMY; PRIORITY JOURNAL; THORAX SURGERY;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; REMISSION INDUCTION;

EID: 33745231177     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01408.x     Document Type: Article

References (9)

1. Vogelzang N Stadler W. Kidney cancer. Lancet 1998 352 : 1691 6.
2. Escudier B Chevreau C Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J. Clin. Oncol. 1999 17 : 2039 43.
3. Vuky J Motzer RJ. Cytokine therapy in renal cell cancer. Urol. Oncol. 2000 5 : 249 57.
4. Aso Y Tasaki H Umeda T Marumo K. A phase II study of S-6820 (recombinant interleukin-2) on renal cell carcinoma. Biotheraphy 1989 3 : 999 1007.
5. Takaoka A Hayakawa A Yanai H et al. Integration of interferon-α/ β signaling to p53 responses in tumor suppression and antiviral defence. Nature 2003 424 : 516 23.
6. Aso Y Homma Y Tazaki H et al. A phase II trial of S-6820 (recombinant interleukin-2) on renal cell carcinoma refractory to interferon. Jpn J. Urol. Surg. 1995 8 : 75 86 MB Regan M Mcdermott D. Update on the role of interleukin 2 and othercytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 2004 10 ( Suppl. 6342s 6s.
7. Whittington R Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993 46 : 446 514.
8. Negrier S Escudier B Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N. Engl. J. Med. 1998 338 : 1272 8.
9. Atzpodien J Kirchner H Jonas U et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 2004 22 : 1188 94.